Eupraxia Pharmaceuticals (EPRX) Announces CFO Succession
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Eupraxia Pharmaceuticals Announces CFO Succession
February 18, 2025 7:00 AM EST-Â Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role
VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ -Â Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately.
... More